Bristol-Myers Squibb Co (NYSE: BMY) started the day on Thursday, with a price increase of 5.91% at $55.77, before settling in for the price of $52.66 at the close. Taking a more long-term approach, BMY posted a 52-week range of $39.35-$55.03.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 16.92%. Meanwhile, its Annual Earning per share during the time was 5.14%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -89.96%. This publicly-traded company’s shares outstanding now amounts to $2.03 billion, simultaneously with a float of $2.03 billion. The organization now has a market capitalization sitting at $113.07 billion. At the time of writing, stock’s 50-day Moving Average stood at $51.09, while the 200-day Moving Average is $47.92.
Bristol-Myers Squibb Co (BMY) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – General Industry. Bristol-Myers Squibb Co’s current insider ownership accounts for 0.08%, in contrast to 77.25% institutional ownership. According to the most recent insider trade that took place on Dec 05 ’23, this organization’s Chief Executive Officer bought 2,000 shares at the rate of 49.78, making the entire transaction reach 99,560 in total value, affecting insider ownership by 82,672. Preceding that transaction, on Nov 28 ’23, Company’s Chief Executive Officer bought 3,071 for 48.86, making the whole transaction’s value amount to 150,049. This particular insider is now the holder of 79,384 in total.
Bristol-Myers Squibb Co (BMY) Earnings and Revenue Records
Bristol-Myers Squibb Co’s EPS decrease for this current 12-month fiscal period is -89.96% and is forecasted to reach 6.98 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -4.21% through the next 5 years, which can be compared against the 5.14% growth it accomplished over the previous five years trading on the market.
Bristol-Myers Squibb Co (NYSE: BMY) Trading Performance Indicators
Let’s observe the current performance indicators for Bristol-Myers Squibb Co (BMY). It’s Quick Ratio in the last reported quarter now stands at 1.02. The Stock has managed to achieve an average true range (ATR) of 1.23. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.43. Similarly, its price to free cash flow for trailing twelve months is now 8.73.
In the same vein, BMY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.26, a figure that is expected to reach 1.51 in the next quarter, and analysts are predicting that it will be 6.98 at the market close of one year from today.
Technical Analysis of Bristol-Myers Squibb Co (BMY)
If we take a close look at the recent performances of Bristol-Myers Squibb Co (NYSE: BMY), its last 5-days Average volume was 10.49 million that shows plunge from its year to date volume of 14.49 million. During the previous 9 days, stock’s Stochastic %D was recorded 60.88% While, its Average True Range was 1.28.
Raw Stochastic average of Bristol-Myers Squibb Co (BMY) in the period of the previous 100 days is set at 97.45%, which indicates a major rise in contrast to 91.21% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 27.99% that was lower than 29.96% volatility it exhibited in the past 100-days period.
